Just adding the
2nd part from Healy Rising Cort Johnson’s blog on Rinvoq.
https://www.healthrising.org/blog/2...8624653db6d460451b2fa1dc008a8#comment-1107042
There is an interesting remark from Dr Herbert Renz-Polster in comments
Dr Herbert Renz-Polster
Fact is that we know next to nothing about cytokines in ME/CFS. These molecules have short half-lifes and are being produced in response to immune challenges. It is therefore to be expected that their titers may be completely different between, let´s say, clinical baseline and PEM. These fluctuations (which can be enormous) could be one of the reasons why measuring cytokines in ME/CFS patient groups has not yielded any meaningful results.
It is sad to say but it´s true: we still have no systematic longitudinal description of ME/CFS – and this haunts ME/CFS research again and agai
This is a very interesting remark - and a big problem with a lot of ME CFS research: not measuring at baseline vs during PEM crash.
So just checked AI FWIW and it’s really short:
“Many cytokines have a short half-life, typically ranging from minutes to a few hours.”
Heightened cytokine levels during PEM seems very plausible, just going off my ‘gut feeling’. During a PEM crash, I literally feel a lot of inflammation (e.g. joints, brain, gut, muscles, etc) and pain.
And it might also be (partially) the reason of the flu-ish type symptoms ??
I understand that she felt awful on the Rinvoq and so felt better when she stopped taking it. But could wiping out the white blood cells and getting new ones have caused the remission? I think versions of that was the rationale of rituximab in ME/CFS and then, when rituximab didn't work, there was the thought that the plasma cells might need to be replaced as might be achieved with a CAR-T therapy.
Regarding your comment, it also reminds me of Cyclophosphamide (and the experience of patients I talked to who had recovered after Cyclo).
A very intensive course of immune suppression / even cytotoxic drugs can reverse illness in a relatively short time.
Not going to speculate which mechanism, but there might be an analogy.
LAST comment/question :
I myself have taken a short 3 month course with Filgotinib - which did not affect me much, positive or negative (I am very severe). Did not feel much like any immune suppression.
I was wondering what exactly the difference is in potency and target mechanisms between Filgotinib and Rinvoq. And if that makes the difference?
As the immunosuppressive effect of JAK inhibitors varies by selectivity.
-
Filgotinib, with focus selectivity for JAK1, is less immunosuppressive than Rinvoq - with less significant effects on infections, viral reactivations, or immune cell levels.
The question is:
- did stronger immune suppression by Rinvoq (incl. JAK2 and JAK3) help “reset the immune system”, contributing to Patient Jen’s improvement?
- Or was it primarily the JAK1 inhibition (like Filgotinib) ?
- Or “idiosyncratic toxicity flipping something completely unrelated” ?